Journal profile · Radiology, Nuclear Medicine & Medical Imaging
Strahlentherapie und Onkologie
ISSN 0179-7158 · eISSN 1439-099X · Springer Berlin Heidelberg · GERMANY · Monthly · Founded 1997
Strahlentherapie und Onkologie: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.8; hybrid open access; APC about USD 4,390; median 108 days to acceptance (88 articles, last 24 months); community-reported acceptance: fairly hard; 158 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Strahlentherapie und Onkologie is published by Springer Berlin Heidelberg and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Radiotherapy Techniques, Effects of Radiation Exposure and Head and Neck Cancer Studies, together about 30.1% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research.Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.
From the journal's Aims & Scope
Research area (LetPub): Radiology, Nuclear Medicine & Medical Imaging
Editor-in-chief Markus HechtPublisher website
Editorial board by country: none in mainland China; most named Germany 84, Austria 9, Switzerland 8, Hungary 2, France 1 (107 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Advanced Radiotherapy TechniquesPhysics and Astronomy15.8%
- Effects of Radiation ExposureMedicine7.3%
- Head and Neck Cancer StudiesMedicine7%
- Prostate Cancer Diagnosis and TreatmentMedicine6.2%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology5.5%
- Brain Metastases and TreatmentMedicine5%
- Lung Cancer Diagnosis and TreatmentMedicine4.8%
- Radiation Therapy and DosimetryMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.8LetPub ·
- Impact factor (publisher) 2025
- 2.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.7Publisher website ·
- CiteScore 2026-06
- 4.3LetPub ·
- SJR 2026-06
- 0.77LetPub ·
- SNIP 2026-06
- 1LetPub ·
- h-index
- 63LetPub ·
- h-index
- 90OpenAlex ·
- i10-index
- 2,081OpenAlex ·
- 2-year mean citedness
- 2.38OpenAlex ·
- Self-citation rate
- 10.7%LetPub ·
- Share of gold OA articles
- 65.03%LetPub ·
Volume
- Articles per year
- 121LetPub ·
- Downloads per year (publisher) 2025
- 680,400Publisher website ·
Articles by year OpenAlex count · 4,365 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 109 | 69 | 10 |
| 2025 | 158 | 117 | 305 |
| 2024 | 151 | 106 | 679 |
| 2023 | 150 | 104 | 952 |
| 2022 | 149 | 91 | 1,364 |
| 2021 | 155 | 99 | 1,254 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
108 daysMedian, submission to acceptance · P25–P75 73 days – 146 days
- Acceptance to online
- median 28 days (99 articles)
- Submission to online
- median 139 days
- Sample
- 88 articles with submission and acceptance dates (293 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to first decision
- 9 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,390 / EUR 3,390 / GBP 2,790 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
- DEGRO 2026 Article HighlightsDeadline
What to prepare5 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
Article types accepted6
- case studyStrahlentherapie und Onkologie Original Articles, Short Communications, Letters to the Editor, Case Studies, Review Articles, “Literatur Kommentiert” articles, …Length not stated
- letters to the editorStrahlentherapie und Onkologie Original Articles, Short Communications, Letters to the Editor, Case Studies, Review Articles, “Literatur Kommentiert” articles, …Length not stated
- original articleStrahlentherapie und Onkologie Original Articles, Short Communications, Letters to the Editor, Case Studies, Review Articles, “Literatur Kommentiert” articles, …Length not stated
- protocolStrahlentherapie und Onkologie Original Articles, Short Communications, Letters to the Editor, Case Studies, Review Articles, “Literatur Kommentiert” articles, …Length not stated
- review articleStrahlentherapie und Onkologie Original Articles, Short Communications, Letters to the Editor, Case Studies, Review Articles, “Literatur Kommentiert” articles, …Length not stated
- short communicationStrahlentherapie und Onkologie Original Articles, Short Communications, Letters to the Editor, Case Studies, Review Articles, “Literatur Kommentiert” articles, …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Strahlentherapie und Onkologie, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Berlin Heidelberg
- Country or region
- GERMANY
- Language
- Multi-Language
- Frequency
- Monthly
- Founded
- 1997
- ISSN
- 0179-7158
- Electronic ISSN
- 1439-099X
- Society / sponsor
- German Society of Radiation Oncology
- Latest issue on the website
- Volume 202, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Strahlentherapie und Onkologie
What CAS zone is Strahlentherapie und Onkologie in?
In the 2025 upgraded edition of the CAS Journal Ranking, Strahlentherapie und Onkologie is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology / Radiology, Nuclear Medicine & Medical Imaging. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Strahlentherapie und Onkologie?
The latest impact factor listed by LetPub is 2.8; CiteScore 4.3, h-index 90.
How long does peer review take at Strahlentherapie und Onkologie?
Based on the dates recorded on 88 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 108 days (interquartile range 73–146 days); authors report an average review time of 3–8 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Strahlentherapie und Onkologie?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Strahlentherapie und Onkologie based?
Of the 107 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Germany (84), Austria (9) and Switzerland (8). Counted from the institutions listed on the board page; for reference only.
Which databases index Strahlentherapie und Onkologie?
According to LetPub and DOAJ records, Strahlentherapie und Onkologie is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and Current Contents; that list has not been checked against each database.
Is Strahlentherapie und Onkologie open access, and what is the APC?
Strahlentherapie und Onkologie is a hybrid journal. For open-access publication: APC about USD 4,390.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .